AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX)

CAPS Rating: 4 out of 5

ACRX News and Commentary

Caps

How do you think ACRX will perform against the market?

Add Stock to CAPS Watchlist

All Players

57 Outperform
7 Underperform
 

All-Star Players

12 Outperform
3 Underperform
 

Wall Street

1 Outperform
1 Underperform
 

Top ACRX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

zzlangerhans (99.76)
Submitted March 10, 2015

It looks like my reservations about AcelRx when the share price was 7 a few weeks ago were right, although the stock went on to a new six-month high over 9 just before the Sword of Damocles dropped. People or institutions who were buying AcelRx in… More

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

ACRX VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about ACRX.

Recs

0
Member Avatar Speedylove (61.47) Submitted: 1/27/2016 4:46:27 PM : Outperform Start Price: $3.03 ACRX Score: -49.79

Great new pain Mgmt platform

Recs

0
Member Avatar joienpaix (< 20) Submitted: 3/18/2015 4:04:11 PM : Outperform Start Price: $4.26 ACRX Score: -66.67

TP 8

Recs

3
Member Avatar zzlangerhans (99.76) Submitted: 3/10/2015 3:27:40 PM : Outperform Start Price: $5.08 ACRX Score: -76.48

It looks like my reservations about AcelRx when the share price was 7 a few weeks ago were right, although the stock went on to a new six-month high over 9 just before the Sword of Damocles dropped. People or institutions who were buying AcelRx in the 7's and 8's on faith that the company would resubmit their NDA in the first quarter as promised, even as the remaining days ticked away, have a totally different perception of the risk/reward equation than I do. Of course, the dark side to all that rosy optimism is the bitterness and hopelessness that is forcing the share price down double digit percentages for the second day in a row. I don't have a hopelessness barometer to tell we how far the stock will continue to fall without any new fundamental negative information, but I think the share price will turn back once the company clarifies how they will respond to the FDA's requirement for a new trial. I also wouldn't put it past the FDA to reverse themselves on this requirement, although I'm lousy at predicting FDA moves. We purchased 2000 shares at 4.94 for the #zzporte portfolio today.

Leaderboard

Find the members with the highest scoring picks in ACRX.

Score Leader

OklaBoston

OklaBoston (63.81) Score: +162.71

The Score Leader is the player with the highest score across all their picks in ACRX.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
OriginalBarnacle 92.73 6/3/2013 7/1/2013 Underperform 1Y $9.10 -76.92% +48.62% +125.55 0 Comment
SaiyanBroker 85.15 3/15/2013 Underperform NS $4.65 -54.84% +56.30% +111.14 0 Comment
brian3305 58.46 10/23/2012 Underperform 3M $3.14 -33.12% +71.64% +104.76 0 Comment
jackbot 95.32 7/28/2014 Underperform 5Y $6.45 -67.44% +22.98% +90.42 0 Comment
jasonrivera < 20 1/13/2016 Underperform 5Y $3.05 -31.12% +28.67% +59.79 0 Comment
HDTVBG < 20 6/28/2017 Underperform 3W $2.10 0% +0.41% +0.41 0 Comment
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. Teacherman1 < 20 6/7/2017 Outperform 3Y $2.23 -5.62% -0.10% -5.52 0 Comment
mnruby 21.20 5/5/2015 Outperform 5Y $3.03 -30.69% +16.06% -46.76 0 Comment
Fodoto < 20 5/5/2015 Outperform 5Y $3.03 -30.69% +16.06% -46.76 0 Comment
Speedylove 61.47 3/18/2016 Outperform 5Y $3.03 -30.69% +19.10% -49.79 1 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
trackmizuho < 20 2/26/2015 Outperform NS $9.27 -77.35% +15.11% -92.46 0 Comment
TrackUltraLong < 20 1/28/2013 Underperform NS $5.14 -59.14% +62.01% +121.16